We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agenus (AGEN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agenus is one of 892 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Agenus is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AGEN's full-year earnings has moved 352.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AGEN has gained about 6.1% so far this year. At the same time, Medical stocks have lost an average of 4.1%. This shows that Agenus is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Ensign Group (ENSG - Free Report) . The stock is up 12.9% year-to-date.
For Ensign Group, the consensus EPS estimate for the current year has increased 5.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agenus belongs to the Medical - Biomedical and Genetics industry, a group that includes 436 individual stocks and currently sits at #143 in the Zacks Industry Rank. Stocks in this group have gained about 5% so far this year, so AGEN is performing better this group in terms of year-to-date returns.
Ensign Group, however, belongs to the Medical - Nursing Homes industry. Currently, this 2-stock industry is ranked #4. The industry has moved +16.2% so far this year.
Investors with an interest in Medical stocks should continue to track Agenus and Ensign Group. These stocks will be looking to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agenus (AGEN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agenus is one of 892 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Agenus is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AGEN's full-year earnings has moved 352.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AGEN has gained about 6.1% so far this year. At the same time, Medical stocks have lost an average of 4.1%. This shows that Agenus is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Ensign Group (ENSG - Free Report) . The stock is up 12.9% year-to-date.
For Ensign Group, the consensus EPS estimate for the current year has increased 5.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agenus belongs to the Medical - Biomedical and Genetics industry, a group that includes 436 individual stocks and currently sits at #143 in the Zacks Industry Rank. Stocks in this group have gained about 5% so far this year, so AGEN is performing better this group in terms of year-to-date returns.
Ensign Group, however, belongs to the Medical - Nursing Homes industry. Currently, this 2-stock industry is ranked #4. The industry has moved +16.2% so far this year.
Investors with an interest in Medical stocks should continue to track Agenus and Ensign Group. These stocks will be looking to continue their solid performance.